This blog has kept an updated digest pertaining to HCV drug investments on Wall Street. Often the articles on these investment sites are insightful with a quick easy read.
Today Morning Star had a little update for their investors on the much anticipated drug telaprevir. In their article written by Lauren Migliore entitled "Three Upcoming Make-or-Break Biotech Approvals" Vertex's drug Telaprevir has been deemed as the winner in the New HCV drug market. The predicition was Telaprevir will most likely take first prize over Merck's boceprevir. Who knew?. Me and YOU !
Quoted From The Article.......
"Vertex (NasdaqGS:VRTX - News) is close to commercializing its hepatitis C drug telaprevir, part of a new class of therapies that have the potential to revolutionize the way the disease is treated""Vertex's chief rival, Merck (NYSE:MRK - News), is developing a protease inhibitor of its own. We think telaprevir's slightly superior efficacy and convenience profile should give it an advantage with prescribers. However, Vertex has no commercialization experience, and Merck's established salesforce and ability to package the drug with the current standard of care should help even the commercialization playing field. Vertex ranked number 1 on our 2010 biotech takeout list, and we continue to believe the firm would benefit from the sales know-how of a larger pharma player like current partner Johnson & Johnson (NYSE:JNJ - News)."
Related Articles On The Blog:
.
,
No comments:
Post a Comment